Tan Kevin
Tan Kevin's purchase track record
Tan Kevin has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2021 | RNAC | $15K | -43.1% | -73.0% | -8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
Transaction History
| SLDB | ▼ Sell | Open Market | 5,404 | $31K | 2/18/2026 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 10,625 | — | 2/13/2026 | View on chart |
| SLDB | ▼ Sell | Open Market | 14,783 | $95K | 2/4/2026 | View on chart |
| SLDB | ▼ Sell | Open Market | 26,837 | $173K | 2/2/2026 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 33,075 | — | 1/31/2026 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 56,646 | — | 1/29/2026 | View on chart |
| SLDB | ▼ Sell | Open Market | 5,704 | $30K | 1/13/2026 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 11,250 | — | 1/9/2026 | View on chart |
| SLDB | ▼ Sell | Open Market | 3,164 | $13K | 2/14/2025 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 10,625 | — | 2/13/2025 | View on chart |
| SLDB | ▼ Sell | Open Market | 4,073 | $16K | 1/10/2025 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 11,250 | — | 1/9/2025 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 11,250 | — | 1/9/2024 | View on chart |
| SLDB | ▼ Sell | Open Market | 3,935 | $32K | 1/9/2024 | View on chart |
| RNAC | ▲ Buy | Grant | 72,000 | $0 | 1/3/2022 | View on chart |
| RNAC | ▲ Buy | Open Market | 5,000 | $15K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SLDB Featured in After-Market Movers List
Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.
SLDB Featured in After-Market Movers List. Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.